Clever Culture Systems Limited · ASX:CC5
Clever Culture Systems — Shareholder Meeting (November 2019)
11 slides from Clever Culture Systems's shareholder meeting presentation, Nov 27, 2019
Slide 1: Annual General Meeting
Annual General Meeting 27th November 2019 Brent Barnes Managing Director & Chief Executive Officer ASX code: LBT lbtinnovations.com
Slide 2: Disclaimer
Disclaimer This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct. Giv
Slide 3: 2019: Inflection point for growth
2019: Inflection point for growth ✓ Clinically proven ✓ Customer Endorsement • 10,000 patient clinical trial: • Customer key opinion leaders performs better than a human established in AU, EU, US ✓ Regulatory cleared for sale ✓ Early Sales • FDA clearance – May 2019 • St Vincent Hospital, Melbourne
Slide 4: APAS® Independence
APAS® Independence The first and only automated culture plate reader. Powered by AI Available Clinically proven regulatory cleared in US, in a 10,000 patient EU, AU clinical trial Automated plate reading 3x faster than manual culture MRSA - negative plate reading MRSA - positive Slide No. 4 © LBT In
Slide 5: 2019 unlocking global markets
2019 unlocking global markets Instrument available for sale. Customer advocacy established CE Mark Labor Wisplinghoff, Cologne Germany FDA Cleared Hennepin Health TGA Cleared System, St Vincent’s Hospital Minneapolis Melbourne Slide No. 5 © LBT Innovations 2019
Slide 6: Delivering our path to market
Delivering our path to market Strategy: Development, global footprint, product cleared for sale, early sales Engaging Distributors Distributor Appointment in • Routine clinical use in their 2020 market • Demonstrate customer engagement • Initial sales pipeline established • Regulatory cleared produc
Slide 7: Launch markets opportunity
Launch markets opportunity Selling in: US, UK, DE, AU Penetration rate of 4 countries 20% 30% 400 units 600 units Cumulative Cumulative instrument sales instrument sales ~AUD$160M ~AUD$240M ~2,000 labs Software licence, building to Software licence, building to ~AUD$16M p.a. ~AUD$24M p.a. Rest of wo
Slide 8: Experienced Board and Management
Experienced Board and Management Brent Barnes Kate Costello Damian Lismore Simon Arkell Caroline Popper CEO and MD Chairman NED NED NED LBT Board LBT Management Team LBT’s board bring broad knowledge and LBT’s management team bring together experiences to the business, including: specialist skills a
Slide 9: Corporate overview
Corporate overview Key Statistics (Closing on 25 November 2019) Financials Share Price $0.19 per share Current Cash $8.7 million (as at 30 September 2019) 12-month range $0.059 - $0.24 $4 million facility – $2.5m drawn down SAFA Loan Facility Number of shares 235.5 million Low interest rate, 5-year
Slide 10: Investment highlights
Investment highlights • APAS® Independence is the only FDA cleared product using Competitive AI for automated clinical microbiology plate reading positioning strong • Clinically proven through 10,000 patient global clinical trial • Early sales achieved in Australia and Germany Commercial strategy •
Slide 11: LBT Innovations
LBT Innovations Level 8, 44 Waymouth Street Adelaide SA 5000 +61 (0)8 8227 1555 info@lbtinnovations.com lbtinnovations.com
Clever Culture Systems — Shareholder Meeting (November 2019) on 6ix